Investors Purchase High Volume of Novavax Call Options (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) saw unusually large options trading activity on Monday. Stock traders purchased 25,185 call options on the stock. This is an increase of approximately 6% compared to the average daily volume of 23,679 call options.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Novavax from $8.00 to $9.00 and gave the stock an “underweight” rating in a research report on Monday, August 12th. B. Riley reissued a “buy” rating and issued a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Finally, Jefferies Financial Group decreased their target price on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Novavax presently has a consensus rating of “Hold” and a consensus target price of $17.83.

Novavax Price Performance

NASDAQ NVAX opened at $9.01 on Tuesday. Novavax has a 12 month low of $3.53 and a 12 month high of $23.86. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -3.24 and a beta of 2.10. The company’s fifty day moving average price is $11.68 and its two-hundred day moving average price is $12.38.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC bought a new position in Novavax during the 1st quarter valued at $1,499,000. Shah Capital Management boosted its stake in Novavax by 19.0% during the 2nd quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock valued at $122,322,000 after acquiring an additional 1,544,263 shares during the last quarter. Vontobel Holding Ltd. boosted its stake in Novavax by 110.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 498,532 shares of the biopharmaceutical company’s stock valued at $6,296,000 after acquiring an additional 261,464 shares during the last quarter. Squarepoint Ops LLC bought a new position in Novavax during the 2nd quarter valued at $1,251,000. Finally, Edgestream Partners L.P. boosted its stake in Novavax by 23.7% during the 1st quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 2,447 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.